AUS
NZ
UK
CA
USA
IND
Highlights
Vitura Health, listed on the ASX as VIT, has made a significant move to broaden its presence in the telehealth sector by acquiring Candor Medical. Founded by Joel and Dr. Lisa Beckett in 2022, Candor Medical operates as a leading medical cannabis clinic in Australia, providing consultations to approximately 15,000 active patients. This acquisition is set at $5.9 million, with $4 million paid upfront and the remainder over 18 months. The transaction is funded through a placement by Adelaide-based businessman Prof Khalil (Charlie) Shahin, who is part of the wealthy Shahin family. This strategic acquisition will integrate Candor Medical with Vitura's existing platforms, including Doctors on Demand and CDA Clinics.
The deal positions Vitura Health advantageously, considering its existing infrastructure in telehealth and medical cannabis services. Nonetheless, the company remains cautious due to stringent regulations from the Therapeutic Goods Administration (TGA). Despite a 60% decrease in share value over the past year, Vitura's actions are seen as a strategic step in consolidating its market position, as reflected in a recent 7% bounce in its stock.
CSL Faces Mixed Analyst Opinions
CSL (ASX:CSL) has recently been the subject of analysts' debates following its half-year results. While some experts deem the company undervalued, others suggest it is overpriced compared to its global peers. The discussion largely centers around the strengths of CSL's Behring plasma division against the setbacks of the Seqirus arm due to lower flu vaccination rates in the US. Notably, CSL trades at a significant premium within the market.
The company's stock was marked down following the results, yet opinions vary significantly. Analyst Dr. Shane Storey notes the robust performance of CSL's primary divisions but highlights the challenges with Seqirus. Various financial institutions provide differing valuations, ranging from Goldman Sachs' $3.18 valuation focusing on margin expectancy, to Macquarie Equities’ highest estimate at $360 per share. Despite the mixed outlook, there is a consensus that the company holds potential for recovery and growth.
Percheron Therapeutics on a Strategic Hunt
Following the unsuccessful Duchenne muscular disease trial, Percheron Therapeutics (ASX:PER) is actively exploring new clinical programs. During the recent JP Morgan Healthcare Conference, the company reported over 50 potential partnership leads and is prioritizing late-stage programs. With $17 million in cash reserves by December end, Percheron is pursuing strategic alliances to revamp its business model and attract investors.
The company's current focus is on sealing collaborations that can replace the void left by the failed trial. The shareholders are expected to deliberate significant management changes in the upcoming meeting, presenting a pivotal moment for Percheron's leadership and future trajectory in the biotech landscape.
